DOES REDUCED HSV PREVALENCE RESULT IN INCREASED ZOSTER INCIDENCE IN THE US?
DOES REDUCED HSV PREVALENCE RESULT IN INCREASED ZOSTER INCIDENCE IN THE US?
批准号:
10039451
负责人:
Ruth Harbecke
金额:
$24.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-05-22 至 2022-04-30
关键词:
AddressAdultAfferent NeuronsAgeAmino AcidsAntibodiesBiological AssayBiological Specimen BanksBlindnessCD8-Positive T-LymphocytesCenters for Disease Control and Prevention (U.S.)ChickenpoxChickenpox VaccineChildChildhoodClinical TrialsConsensusCytomegalovirusDataDevelopmentDiseaseDistantEpidemiologyEpstein-Barr Virus InfectionsHealthHerpes zoster diseaseHerpesviridaeHerpesvirus 1Herpesvirus Type 3Human Herpesvirus 2Human Herpesvirus 4Human Herpesvirus 6Human Herpesvirus 7ImmuneImmune systemImmunityImmunocompetentIncidenceInfectionLightMeasuresMedicalMorbidity - disease rateNational Health and Nutrition Examination SurveyNested Case-Control StudyOdds RatioPainParticipantPersonsPlacebosPopulationPredispositionPrevalencePreventionPublicationsRandomized Controlled TrialsRecrudescencesRiskSamplingSerologicalSeroprevalencesSerumSeveritiesSimplexvirusSpecimenStrokeStructureT cell responseT-LymphocyteT-Lymphocyte EpitopesTestingTimeTime trendUnited StatesUniversitiesVaccinationVaccinesVirus DiseasesWashingtonWestern BlottingZoster Vaccinearmbiobankcohortcross reactivitypathogenpreventrepositorysextrend
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
This proposal brings together three observations: 1) the increasing incidence of zoster in the
United States, 2) the decreasing seroprevalence of HSV-1 and HSV-2, and 3) the discovery of
extensive T cell cross-reactivity between HSV and VZV. HSV and VZV cause very distinct
illnesses, but do share a low degree of sequence at the amino acid level that underlies immune
cross-reactivity. It is widely accepted that the risk of zoster is inversely correlated with VZV-
specific T cell immunity. We hypothesize that the increasing incidence of zoster over time
reflects decreased cross-reactive immunity elicited by HSV, due to decreasing rates of HSV
infection. We propose a nested case-control study to examine this hypothesis. We will test
baseline samples of participants who developed zoster, and matched controls, from the placebo
arm of the Shingles Prevention Study. This previously-completed study of a candidate zoster
vaccine has a suitable Specimen Repository. We will determine if the seroprevalence of HSV is
lower among cases than among controls. HSV antibody status will be measured with the
University of Washington Western blot, the most accurate test available. Because there is a
large degree of T cell cross-reactivity between VZV and both HSV-1 and HSV-2, Western blot
assays will detect infection with both HSV types. Our Specific Aims are: 1) to test whether
persons who develop zoster are less likely to have prior HSV infection than age, sex and health-
matched persons without zoster, and 2) to test whether among persons who develop zoster, the
disease is less severe among those that have prior HSV infection than those that are HSV
seronegative. Power calculations indicate that we will be able to detect a 1.8 odds ratio of HSV
infection in the control arm using serum samples from 200 persons that developed zoster and
400 controls for Aim 1, and a 92% power to detect 1.4X increase in zoster pain for Aim 2. This
project will shed light on whether the population-wide temporal changes in the epidemiology of
one herpesvirus have an impact on the morbidity of a distantly sequence-related pathogen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOES REDUCED HSV PREVALENCE RESULT IN INCREASED ZOSTER INCIDENCE IN THE US?
-
批准号:10170235
-
项目类别:
-
资助金额:$19.22万
-
财政年份:2020
-
负责人:Ruth Harbecke
-
依托单位:
海外基金